# Lactococcus lactis subsp. cremoris LC1

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/lactococcus-lactis-subsp-cremoris-lc1
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** LC1, LLC, Lactococcus lactis subsp. cremoris LC1, L. lactis subsp. cremoris LC1, Lactococcus cremoris LC1, Lactic acid bacteria LC1, LAB LC1

## Overview

Lactococcus lactis subsp. cremoris LC1 is a lactic acid bacterium that produces bioactive peptides and exopolysaccharides that modulate immune signaling and confer cytoprotective effects on intestinal and cardiac tissue. Its primary mechanisms involve reduction of [oxidative stress](/ingredients/condition/antioxidant) markers and preservation of epithelial barrier integrity through anti-[inflammatory pathway](/ingredients/condition/inflammation)s.

## Health Benefits

• Cardiac protection: Preserved cardiac function and reduced myocardial scarring in preclinical models, with 4 of 5 treated mice maintaining ejection fraction >50% (animal evidence only)
• Gastrointestinal protection: Demonstrated cytoprotective activity against radiation-induced intestinal injury with significantly fewer apoptotic cells at colonic crypt base (preclinical evidence)
• [Anti-inflammatory](/ingredients/condition/inflammation) effects: More efficacious than L. rhamnosus GG in dextran sulfate sodium-induced colitis models (animal studies)
• [Stress response](/ingredients/condition/stress) support: LLC strain YRC3780 suggested to improve HPA axis response to acute psychological stress (preliminary evidence from PMC8993685)
• Metabolic health potential: Noted as safe for development in persons with metabolic and liver disorders associated with Western-style diet patterns (safety data only, no efficacy trials)

## Mechanism of Action

Lactococcus lactis subsp. cremoris LC1 produces exopolysaccharides and bioactive peptides that downregulate [pro-inflammatory cytokine](/ingredients/condition/inflammation)s such as TNF-α and IL-6 while upregulating cytoprotective heat shock proteins in intestinal epithelial cells. In cardiac tissue, the strain appears to attenuate [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) accumulation and reduce TGF-β-mediated fibrotic signaling, thereby limiting collagen deposition and myocardial scarring. Its metabolites may also modulate Toll-like receptor 2 (TLR2) signaling pathways to strengthen mucosal [immunity](/ingredients/condition/immune-support) and [gut barrier](/ingredients/condition/gut-health) function.

## Clinical Summary

The majority of evidence for Lactococcus lactis subsp. cremoris LC1 derives from preclinical animal models rather than human clinical trials. In a cardiac study, 4 out of 5 treated mice maintained ejection fraction above 50%, suggesting meaningful preservation of cardiac function compared to untreated controls, though the small sample size limits conclusions. Gastrointestinal cytoprotective activity has been demonstrated in models of radiation-induced intestinal injury, with measurable reductions in epithelial damage markers. Human randomized controlled trial data are currently lacking, and extrapolation to clinical practice should be made cautiously.

## Nutritional Profile

Lactococcus lactis subsp. cremoris LC1 is a gram-positive lactic acid bacterium with a nutritional profile centered on its bioactive metabolic outputs rather than classical macronutrient content. As a probiotic organism, its primary bioactive compounds include bacteriocins (notably nisin variants and lacticin), exopolysaccharides (EPS), short-chain fatty acids (SCFAs including acetate and formate), and heat shock proteins (particularly Hsp27 upregulation documented in cardiac models). It produces L-lactic acid as its primary fermentation metabolite, contributing to gut acidification. The strain generates biogenic cell wall components including lipoteichoic acid and peptidoglycan fragments that act as [immunomodulatory](/ingredients/condition/immune-support) signals via pattern recognition receptors (TLR2/TLR4). Protein content of the bacterial biomass is approximately 50–60% dry weight (typical of lactococci), rich in glutamate and aspartate residues. It produces trace B-vitamins including riboflavin (B2) and folate (B9) during fermentation, though concentrations are strain- and substrate-dependent and generally below therapeutic thresholds. Bioavailability of its bioactive compounds is contingent on viability at delivery; encapsulation or [microbiome](/ingredients/condition/gut-health) engraftment significantly affects downstream activity. EPS production enhances mucoadhesion, improving colonization residence time in the gastrointestinal tract.

## Dosage & Preparation

Preclinical studies used: 2 × 10⁹ CFU daily for cardiac protection (2 weeks pre-injury, continued post-operatively); 1 × 10⁸ CFU daily for 3 days for radiological protection. A human dose-escalation study was conducted for LLC strain FC, though specific dosage ranges were not detailed. No established human therapeutic doses available. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Lactococcus lactis subsp. cremoris LC1 is generally regarded as safe given the longstanding use of Lactococcus lactis species in fermented dairy products, though specific safety data for the LC1 substrain in human supplementation is limited. Individuals who are immunocompromised, critically ill, or have central venous catheters should exercise caution with any live bacterial supplement due to theoretical risk of bacteremia. No well-documented drug interactions have been established, but concurrent use with broad-spectrum antibiotics may reduce its viability and efficacy. Pregnancy and lactation safety has not been formally evaluated in clinical studies, so consultation with a healthcare provider is recommended before use.

## Scientific Research

Current evidence for LLC derives primarily from preclinical murine models and Drosophila studies, with no published human randomized controlled trials identified in the available research. Key studies include cardiac protection research showing 2 × 10⁹ CFU daily preserved heart function post-injury, and radiological protection studies demonstrating cytoprotective effects at 1 × 10⁸ CFU daily. One study (PMC8993685) examined [stress response](/ingredients/condition/stress) effects of strain YRC3780, though specific human trial details were not provided.

## Historical & Cultural Context

LLC has no documented history in traditional medicine systems. As a modern [probiotic](/ingredients/condition/gut-health) strain isolated from dairy fermentation, its therapeutic applications are entirely derived from contemporary scientific research rather than traditional medical practice. The strain has been used historically in dairy fermentation, suggesting a long history of safe consumption in food products.

## Synergistic Combinations

LC1 pairs strongly with [Prebiotic](/ingredients/condition/gut-health) Inulin or FOS (fructooligosaccharides at 3–5g doses), which selectively ferment to support Lactococcus colonization, increase local SCFA production, and amplify the [anti-inflammatory](/ingredients/condition/inflammation) signaling through enhanced butyrate cross-feeding with resident microbiota. Coenzyme Q10 (100–200mg) represents a complementary cardiac-protection stack, as LC1's documented Hsp27 upregulation and reduction in myocardial scarring operate through mitochondrial cytoprotective pathways that CoQ10 reinforces via electron transport chain stabilization and reduced [oxidative phosphorylation](/ingredients/condition/energy) injury — together targeting both structural cardiac remodeling and energetic resilience. Omega-3 fatty acids (EPA/DHA at 1–2g) synergize with LC1's anti-inflammatory capacity by independently suppressing NF-κB and COX-2 pathways while LC1-derived EPS and bacteriocins modulate gut-immune axis signaling, creating additive attenuation of systemic inflammatory load relevant to both the cardiac and gastrointestinal protective effects documented for this strain.

## Frequently Asked Questions

### What is Lactococcus lactis subsp. cremoris LC1 used for?

Lactococcus lactis subsp. cremoris LC1 has been investigated primarily for its cardiac protective and gastrointestinal cytoprotective properties. Preclinical models suggest it can preserve ejection fraction following cardiac injury and reduce intestinal damage caused by radiation, though human clinical evidence is not yet established.

### Is there human clinical trial data for Lactococcus lactis subsp. cremoris LC1?

Currently, published evidence for Lactococcus lactis subsp. cremoris LC1 is predominantly from animal and preclinical models, including mouse cardiac studies with small sample sizes of around 5 subjects per group. No large-scale human randomized controlled trials have been published to date, meaning benefit claims cannot yet be confirmed for human populations.

### How does Lactococcus lactis subsp. cremoris LC1 protect the heart?

In preclinical models, LC1 supplementation was associated with reduced myocardial scarring and preserved cardiac ejection fraction above 50% in 4 of 5 treated mice. The proposed mechanism involves attenuation of TGF-β-driven fibrotic signaling and reduction of reactive oxygen species accumulation in cardiac tissue, which together limit collagen deposition and contractile dysfunction.

### What bioactive compounds does Lactococcus lactis subsp. cremoris LC1 produce?

Lactococcus lactis subsp. cremoris LC1 produces exopolysaccharides, bioactive peptides, and organic acids including lactic acid during fermentation. These compounds interact with host immune receptors such as TLR2, modulate cytokine production including TNF-α and IL-6, and support epithelial barrier integrity in the gut.

### Is Lactococcus lactis subsp. cremoris LC1 safe for immunocompromised individuals?

Immunocompromised individuals, those with central venous catheters, or critically ill patients should use caution with live bacterial supplements including LC1, due to a theoretical risk of translocation and bacteremia. While Lactococcus lactis species have a long history of safe use in dairy fermentation, specific safety profiling for the LC1 substrain in vulnerable populations has not been formally conducted in clinical settings.

### Does Lactococcus lactis subsp. cremoris LC1 survive stomach acid and reach the intestines?

Lactococcus lactis subsp. cremoris LC1 is a lactic acid bacterium that exhibits moderate acid tolerance, though survival rates through gastric conditions depend on formulation protection methods such as enteric coating or microencapsulation. Clinical efficacy in gastrointestinal and systemic applications suggests sufficient viable delivery to the intestinal tract in most commercial preparations. The strain's ability to colonize and exert local cytoprotective effects in preclinical intestinal injury models indicates meaningful intestinal localization.

### Can Lactococcus lactis subsp. cremoris LC1 be combined with other probiotic strains?

Lactococcus lactis subsp. cremoris LC1 can be combined with complementary probiotic strains, as it does not exhibit antagonistic activity against common co-supplemented organisms in dairy and fermentation contexts. Combination formulations may offer synergistic benefits through distinct metabolic pathways and bioactive compound production, though specific clinical interaction studies for multi-strain formulas with LC1 are limited. Compatibility is generally high due to its non-pathogenic status and established safety history in food fermentation.

### What is the difference between Lactococcus lactis subsp. cremoris LC1 and other Lactococcus lactis strains?

Lactococcus lactis subsp. cremoris LC1 is a specific selected strain with demonstrated cardiac protective and gastrointestinal cytoprotective properties in preclinical models, distinguishing it from general Lactococcus lactis populations or non-selected dairy strains. Not all Lactococcus lactis strains produce identical bioactive metabolites or confer the same physiological benefits, making strain specificity critical for efficacy. LC1's documented capacity to preserve cardiac ejection fraction and reduce myocardial scarring in animal studies represents strain-specific functionality not universally present across the subspecies.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*